FDA Updates Its General Wellness Guidance: What Changed and Why It Matters

The FDA has released an updated version of its General Wellness guidance, a policy document that has long shaped how wellness products, wearables, and digital health tools are regulated in the United States. While the core framework remains intact, the revised guidance reflects how much the wellness and digital health landscape has evolved since the original version. 

For companies operating at the intersection of wellness, technology, and health data, the changes are meaningful. Below is a clear breakdown of what stayed the same, what shifted, and why it matters. 

The Foundation Stayed the Same 

Both the original and updated guidance rely on the same two-part framework for determining whether a product qualifies as a general wellness product and therefore falls outside FDA medical device regulation. 

A product may qualify if it: 

1. Is intended only for general wellness use, such as maintaining or encouraging a healthy lifestyle. 

2. Presents a low risk to users and others. 

This fundamental test has not changed. Products that are invasive, implanted, or pose inherent safety risks without controls remain outside the general wellness category. The FDA also continues to draw a clear line between wellness products and those intended to diagnose, treat, mitigate, cure, or prevent disease.

What has changed is how the FDA applies this framework to modern technologies. 

Broader Acceptance of Physiologic Measurements 

Under earlier versions of the guidance, products that measured or displayed physiological parameters such as heart rate, blood pressure, or oxygen saturation often raised red flags. Even when positioned as lifestyle tools, these measurements were closely associated with clinical decision-making and frequently triggered medical device concerns. 

The updated guidance takes a more nuanced approach. 

The FDA now clarifies that non-invasive products that measure or estimate physiological signals can still qualify as general wellness products if they are clearly intended for wellness use and meet specific guardrails. These include: 

• No claims related to diagnosing or managing a disease or condition 

• No representation as a substitute for a regulated medical device 

• No clinical thresholds, alarms, or language suggesting abnormal or dangerous values 

• Outputs framed around trends, lifestyle insights, or general health awareness 

  
  

In other words, the presence of physiological data alone is no longer the deciding factor. How that data is framed, interpreted, and communicated now carries more weight. 

 

Messaging and Context Matter More Than Ever 

One of the most important shifts in the updated guidance is the FDA’s emphasis on context over raw data. 

Previously, the type of data collected often drove regulatory classification. In the revised guidance, the FDA makes it clear that measurement alone does not determine whether a product is a medical device. 

Instead, regulators are focused on: 

• Whether outputs are presented as wellness insights rather than clinical conclusions 

• Whether claims imply diagnosis, treatment, or medical decision-making 

• Whether the product directs users toward specific medical actions 

  
  

For example, showing trends related to activity, recovery, or general cardiovascular wellness may fall within general wellness. Interpreting the same data as abnormal, risky, or requiring medical intervention likely does not. 

For companies, this places increased importance on product design, labeling, and marketing language. 

The Lines the FDA Did Not Move 

Despite the broader flexibility, the updated guidance does not remove key regulatory boundaries. 

Products remain regulated if they: 

• Are invasive or implanted 

• Make explicit or implicit disease claims 

• Function as a replacement for clinical-grade diagnostic tools 

• Provide alerts or recommendations that suggest medical treatment or monitoring 

  
  

The FDA’s intent is not deregulation across the board. It is clarification. 

What This Means for Wellness and Digital Health Companies 

The updated guidance offers opportunity, but only for companies willing to be disciplined. 

Product positioning now plays a critical role in regulatory risk. Claims, user interface language, and marketing materials must align tightly with wellness intent. Clinical terminology, even when accurate, can quickly move a product out of the general wellness category. 

Companies should also expect greater scrutiny of how data is contextualized. Trend-based insights and educational framing are far safer than conclusions that resemble medical judgment. 

Most importantly, this guidance reinforces a long-standing reality: regulatory strategy should be considered early, not retrofitted after launch. 

Bottom Line 

The FDA did not rewrite the general wellness framework. It modernized how that framework applies to today’s technology. 

By focusing on intent, context, and communication rather than data type alone, the updated guidance gives wellness and digital health innovators a clearer path forward. That path is still narrow, but it is more predictable for those who understand the rules.

Need help assessing where your product falls under the updated guidance? If you are developing or marketing a wellness or digital health product and want to pressure-test your claims, positioning, or regulatory risk, now is the time to take a closer look. A proactive review can help you move faster with more confidence and fewer surprises down the road. 

Feel free to reach out if you would like support navigating the updated General Wellness framework or evaluating how these changes apply to your product.